Microcap Ledger BioRestorative Therapies, Inc. $BRTX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Services-Misc Health & Allied Services, NEC
- Headquarters
- Melville, NY
- Fiscal year end
- December 31
- Shares outstanding
- 25,478,170 [10-Q 2026-05-14]
What the company doesAI summary of filing
BioRestorative Therapies develops cell-based therapeutic products using adult stem cells. The company is clinical-stage, conducting a Phase 2 trial of BRTX-100, an autologous mesenchymal stem cell product for chronic lower back pain from degenerative disc disease, which has received FDA Fast Track designation. The company also has a pre-clinical program called ThermoStem targeting metabolic disorders using brown adipose-derived stem cells, and operates a commercial biocosmeceuticals business selling a cell-based secretome product for cosmetic use. The company has received over $16 million in gross proceeds from various capital raises but has not generated significant revenues to date and requires additional financing to complete its clinical trials and operations. [10-K 2026-03-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 3 months to Mar 2026 | $23.2K | −$2.15M | −$3.81M | $3.11M | [10-Q 2026-05-14] |
| FY ended Dec 2025 | $359.7K | −$14.24M | −$10.79M | $1.51M | [10-K 2026-03-26] |
| FY ended Dec 2024 | $401.0K | −$8.98M | −$8.23M | $547.9K | [10-K 2026-03-26] |
- Quarterly cash burn
- −$3.81M
- Cash runway Estimate
- ~2.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-08-12 | 6,919,919 | [10-Q 2024-08-13] |
| 2024-11-12 | 6,919,919 | [10-Q 2024-11-12] |
| 2025-03-26 | 7,504,780 | [10-K 2025-03-28] |
| 2025-05-13 | 7,504,780 | [10-Q 2025-05-14] |
| 2025-08-11 | 7,978,117 | [10-Q 2025-08-12] |
| 2025-11-11 | 8,876,242 | [10-Q 2025-11-12] |
| 2026-03-23 | 25,478,170 | [10-K 2026-03-26] |
| 2026-05-14 | 25,478,170 | [10-Q 2026-05-14] |
- Shelf registration
- S-1 filed 2026-02-09; declared effective 2026-04-28 [S-1 2026-02-09]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-08-25. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-08-25 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-08-25] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2025-10-06 | Silva Francisco | grant | 11,719 | $1.60 | [4 2025-10-20] |
| 2025-10-06 | Alstodt Lance | grant | 15,625 | $1.60 | [4 2025-10-20] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | 8-K | Director or officer change |
| 2026-09-11 | 8-K | Director or officer change |
| 2026-09-10 | 8-K | Auditor change; Other events |
| 2026-09-02 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change; Regulation FD disclosure |
| 2026-09-02 | 8-K | Auditor change; Director or officer change |
| 2026-08-25 | 8-K | Listing notice or transfer |
| 2026-08-14 | NT 10-Q | Notice of late quarterly report |
| 2026-08-14 | 8-K | Other events |
| 2026-08-03 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-16 | 8-K | Director or officer change |
| 2026-06-12 | 8-K | Director or officer change |
| 2026-06-12 | 8-K | Material agreement entered; Director or officer change |
Alerts for $BRTX
Email me when BioRestorative Therapies, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.